| Sep 17 |
Jim Cramer Says Regeneron Pharmaceuticals Inc. (REGN)’s Oncology Portfolio is Beautiful
|
| Sep 16 |
Regeneron, SNY Win FDA Approval for a Broader Dupixent Label
|
| Sep 16 |
ESMO 2024: Regeneron’s melanoma combo therapy benefit continues beyond two years
|
| Sep 16 |
Regeneron’s Dupixent approved as first adolescent CRSwNP treatment
|
| Sep 13 |
Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
|
| Sep 13 |
Pharma Stock Roundup: FDA Approves J&J's Tremfya for Ulcerative Colitis & More
|
| Sep 11 |
Sanofi, Regeneron's Dupixent Meets Late-Stage Urticaria Study Goals
|
| Sep 11 |
Regeneron, Sanofi report mixed outcomes in late-stage trials for Dupixent
|
| Sep 11 |
EYLEA HD® (aflibercept) Injection 8 mg Data at EURETINA Reinforce Long-term Durability, Sustained Fluid Control and Safety Profile
|
| Sep 11 |
Prediction: These 2 Companies Will Split Their Stocks by 2027
|
